The Geneva Association Report: Prolonged Low Interest Rates a Complex but Manageable Headwind for Life Insurers
The effects of prolonged low interest rates on life insurers represent a complex but manageable headwind for the industry as it continues to adapt its business model in response, according to a new research report published today by The Geneva Association, the leading international think tank of the insurance industry.
The study The ‘Low for Long’ Challenge: Socio-economic implications and the life insurance industry’s response, based on insights from senior industry leaders, analyses the impact that low interest rates have on life insurers, their customers and society. The broader context centres on the question of whether an extended period of low interest rates could impair the socio-economic role life insurers have played for many years.
Anna Maria D’Hulster, Secretary General of The Geneva Association, said: “The role of life insurance in helping individuals achieve peace of mind and financial security is significant. In a low interest rate environment, insurers have an even bigger role to play as individuals may struggle to find reliable retirement solutions with appropriate returns. Life insurers have come a long way in tackling the current challenges exposed by the current macro-financial environment, and industry leaders are reasonably confident that life insurance will continue to play its socio-economic role.”
Low interest rates penalise individual retirement savings and may cause insurers to withdraw certain retirement savings products (especially those with performance guarantees) that customers had previously relied upon, but which can no longer be adequately priced in the current macro-financial environment. At the same time, there is an increasing likelihood that governments will have to cut public retirement benefits that were granted in the past. These factors combined put the socio-economic role of life insurers at centre stage.
Daniel Hofmann, Senior Advisor – Insurance Economics at The Geneva Association and principal author of the report, commented: “In our conversations with senior executives they also made it clear that customers must see value in product offerings. Failing to reach this goal would put at risk the socio-economic role of life insurance at a critical time when ageing societies face a growing need to access dependable and sustainable retirement solutions.”
Interviewed executives highlighted three key priorities as part of the industry’s response to the low interest rate environment:
- In-force business management, the goal of which is to create more value for customers and other stakeholders by better managing businesses that may have been on the books for decades.
- Cost reduction, where one of the major challenges arises from complicated IT legacy systems built decades ago. Respondents believed that new technologies represent an opportunity to improve the cost efficiency of life insurers.
- A new business mix, with the aim to rebalance the portfolio toward products that are better adapted to the current interest rate environment.
The core of the report is based on in-depth interviews with 18 senior executives of large, globally active life insurers, complemented by a quantitative survey completed by all participants. The report was further complemented by industry statistics and balance sheet data of a sample of the five largest life insurers in six key markets (Germany, France, Italy, Japan, the U.S. and the U.K.).
Interviews with Anna Maria D’Hulster, Secretary General, and Daniel Hofmann, principal author of the report
The Geneva Association
Director of Communications
+41 44 200 4906
+41 44 200 4996
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 16:00 | Tiedote
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice
Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 15:47 | Tiedote
The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i
Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 13:18 | Tiedote
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,
Dr Amal Al Qubaisi Wins Parliamentarian Excellence Award as Best President of Arab Parliament11.12.2017 12:41 | Tiedote
The Arab Inter-Parliamentary Union (AIPU) has honored Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the United Arab Emirates parliament, with the Parliamentarian Excellence Award in the Presidents of Arab Parliaments category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005411/en/ Her Excellency Dr Amal Al Qubaisi, Speaker of the Federal National Council (FNC) – the UAE parliament (Photo: AETOSWire) The award honors Al Qubaisi as ‘first female leader of a parliament in the Arab world’, celebrating her achievements on a national, regional and global scale, as well as the accomplishments made by FNC under her leadership. It also acknowledges the pioneering parliamentarian initiatives, projects and programs she has spearheaded and her significant contr
Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma11.12.2017 11:00 | Tiedote
New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were presented this weekend at the 59th American Society of Hematology (ASH) Annual Meeting. The results showed that rapid infusion of CT-P10 was well-tolerated across all patient groups and patients could be safely switched from reference rituximab to CT-P10 without reverting to slower infusion rates1. The independent study examined the infusion-related reactions (IRRs) in three different patient groups: rituximab naive, those switching directly from reference rituximab to CT-P10, and those that received their last dose of reference rituximab at least 6 months prior to the study.1 The administration of rituximab is associated with IRRs which occur most frequently during the first infusion. To reduce the risk of IRRs, it is the man
Financial Market Regulator Grants EU Payment License to DIMOCO Payment Services11.12.2017 11:00 | Tiedote
The Austrian Financial Market Authority (FMA) granted a license under the Payment Service Act to DIMOCO Payment Services . The awarded license allows DIMOCO Payment Services to contribute to the payment value chain, offering merchants a single technical interface and a unified clearing & settlement process for many payment methods, including credit cards, online bank transfers, SEPA and direct debit cards. “We differ from most PSPs in the global payments ecosystem with our personal touch,” said Boris Kersten, Managing Director of DIMOCO Payment Services. “We proactively and personally monitor the overall payment process. In addition to monitoring individual transactions, we make recommendations and take actions to decrease chargebacks and fraudulent transactions. This process is not simply left to algorithms, the human element is added to the mix resulting in the protec
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme